About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristant #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Senator Kyl’s Patent Reform Bill Introduced Today | Main | BIO Praises Senator Kyl's Patent Reform Bill »

September 25, 2008

Comments

Don,

GSK's brief again exposes the sheer sophistry and lawlessness of the USPTO's position on these continuation-claim Rules. And how the USPTO is going to address GSK's arguments at oral argument with a straight face in view of what should be blistering questions from the Federal Circuit bench should be a sight to behold and hear.

What is also really sad is how much ink, effort, money and frustration has been spent by us in the private sector to bring these unlawful and unthoughtful Rules to ground. We can only count the days to when the current USPTO hierarchy is gone, and with it hopefully this misguided attitude about the Rule of Law.

The comments to this entry are closed.

May 2019

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31